Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups.

Date publication

janvier 2022

Journal

BMC surgery

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MARCHAL Frédéric , Dr KAMINSKY Marie-Christine

Tous les auteurs :
Gomes David M, Bakrin N, Salleron J, Kaminsky MC, Bereder JM, Tuech JJ, Lehmann K, Mehta S, Glehen O, Marchal F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34996419

Résumé

To investigate the benefit of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of endometrial peritoneal carcinomatosis compared to CRS alone.

Mots clés

Carcinomatosis, Cytoreductive surgery, Endometrial cancer, HIPEC, Peritoneal metastasis

Référence

BMC Surg. 2022 Jan 7;22(1):1